DBV1 Stock Chart & Stats
€12.00
-€0.20(-1.69%)
At close: 4:00 PM EDT
€12.00
-€0.20(-1.69%)
Day’s Range― - ―
52-Week Range€7.65 - €24.40
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€659.46M
Enterprise Value€1.09K
Total Cash (Recent Filing)€174.90M
Total Debt (Recent Filing)€21.00M
Price to Earnings (P/E)―
Beta-0.41
Next Earnings
Oct 28, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding62,877,760
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)9.81
Price to Sales (P/S)0.00
P/FCF Ratio-13.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€41.19Price Target Upside243.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.83
Revenue Forecast (FY)€3.78M
Bulls Say, Bears Say
Bulls Say
Low LeverageLow debt relative to equity and a sizable asset base give DBV a financial cushion against operating losses and reduce immediate debt-service pressure. This flexibility can help preserve strategic options while the company advances its clinical and regulatory programs, although it does not solve the funding need created by losses.
Proprietary PlatformThe proprietary Viaskin platform gives DBV a defined technology base focused on delivering immunotherapy through the skin. If development succeeds, a differentiated delivery approach could support expansion across food allergies and other immune-mediated conditions, creating longer-term pipeline potential.
FDA EngagementFDA engagement without a request for additional data is constructive for the lead program’s regulatory path. Guidance on organizing existing chemistry, manufacturing, controls, and biostatistical information may improve submission readiness and preserve a route toward potential pediatric commercialization.
Bears Say
No Current RevenueZero current revenue and materially wider losses show that DBV has not yet achieved commercial scale and remains dependent on development-stage economics. Until a product generates meaningful sales, earnings power cannot fund operations, leaving results highly sensitive to clinical and regulatory execution.
Accelerating Cash BurnThe sharp deterioration in operating and free cash flow indicates that DBV is consuming capital at an accelerating rate. Sustained cash burn can require repeated external financing, increasing dilution risk and potentially constraining investment in clinical programs if capital access becomes less favorable.
Negative Shareholder ReturnsPersistently negative return on equity indicates that shareholder capital is currently supporting losses rather than producing returns. The substantial TTM figure and fluctuating equity base reinforce the risk that future capital raising may be needed, potentially weakening per-share ownership and financial stability.
DBV Technologies SA - American News
DBV1 FAQ
What was DBV Technologies SA - American’s price range in the past 12 months?
DBV Technologies SA - American lowest stock price was €7.65 and its highest was €24.40 in the past 12 months.
What is DBV Technologies SA - American’s market cap?
DBV Technologies SA - American’s market cap is €659.46M.
When is DBV Technologies SA - American’s upcoming earnings report date?
DBV Technologies SA - American’s upcoming earnings report date is Oct 28, 2026 which is in 44 days.
How were DBV Technologies SA - American’s earnings last quarter?
DBV Technologies SA - American released its earnings results on Jul 16, 2026. The company reported -€0.104 earnings per share for the quarter, missing the consensus estimate of -€0.094 by -€0.01.
Is DBV Technologies SA - American overvalued?
According to Wall Street analysts DBV Technologies SA - American’s price is currently Undervalued.
Does DBV Technologies SA - American pay dividends?
DBV Technologies SA - American does not currently pay dividends.
What is DBV Technologies SA - American’s EPS estimate?
DBV Technologies SA - American’s EPS estimate is -0.12.
How many shares outstanding does DBV Technologies SA - American have?
DBV Technologies SA - American has 62,877,760 shares outstanding.
What happened to DBV Technologies SA - American’s price movement after its last earnings report?
DBV Technologies SA - American reported an EPS of -€0.104 in its last earnings report, missing expectations of -€0.094. Following the earnings report the stock price went down -6.015%.
Which hedge fund is a major shareholder of DBV Technologies SA - American?
Currently, no hedge funds are holding shares in DE:DBV1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DBV Technologies SA - American Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€41.19 (243.29% Upside)
€41.19 (243.29% Upside)
Blogger Sentiment
Bullish
DE:DBV1 Sentiment 100%
Sector Average 61%
Sector Average 61%
Insider Transactions
Sold Shares
Worth €1.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
19.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
55.62%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
DBV Technologies SA - American
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
DBV1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a positive outlook with significant progress in Viaskin Peanut development and financial management. However, regulatory challenges and increased operating expenses pose some concerns. The overall sentiment is cautiously optimistic with a positive tilt due to successful trial milestones and extended cash runway.View all DE:DBV1 earnings summariesDBV1 Stock 12 Month Forecast
Average Price Target
€41.19
▲(243.29% Upside)
Technical Analysis
Larimar Therapeutics
―
Korro Bio
―
4D Molecular Therapeutics
―
―
Lexeo Therapeutics, Inc.
―